We knew our antiserum was not specific for glucagon but others believed that theirs was
Week 3: Increase to the next dose if the previous dose was well tolerated
The FDAs approval of resmetirom changes the MASH drug development landscape for the better after years of failed programs 3
Hes an associate professor at Stanford University School of Medicine and program director of medical weight loss at Palo Alto VA
A substudy published in Nature Medicine enrolled 98 participants with MASLD for 48 weeks (Nature Medicine, 2024): At 12 mg, 93% of participants with fatty liver achieved normal liver fat levels
In this study, we utilize a two-sample MR and colocalization framework to systematically evaluate the causal effects of single, dual, and triple agonism at GLP-1R, GIPR, and GCGR